Korean J Gastroenterol.  2009 Aug;54(2):135-137. 10.4166/kjg.2009.54.2.135.

L-Ornithine and Phenylacetate Synergistically Produce Sustained Reduction in Ammonia and Brain Water in Cirrhotic Rats. Hepatology 2009;50:155-164

• Kim YS

• KMID: 1775970
• DOI: http://doi.org/10.4166/kjg.2009.54.2.135

Abstract

No abstract available.

Reference

1. Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wen-don J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007; 46:1844–1852.

2. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004; 328:1046.

3. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007; 45:549–559.

4. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005; 365:431–433.

5. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007; 46:1853–1862.

6. McFarlane Anderson N, Bennett FI, Alleyne GA. Ammonia production by the small intestine of the rat. Biochim Biophys Acta. 1976; 437:238–243.

7. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology. 1999; 30:636–640.

8. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997; 25:1351–1360.

9. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a metaanalysis. J Gastroenterol Hepatol. 2009; 24:9–14.

10. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroen-trology. 2009; 136:2159–2168.

11. Jalan R, Wright G, Davies NA, Hodges SJ. L-ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses. 2007; 69:1064–1069.

12. Olde Damink SW, Deutz NE, Dejong CH, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neuro-chem Int. 2002; 41:177–188.

13. Restuccia T, Gomez-Anson B, Guevara M, et al. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology. 2004; 39:1613–1622.

14. Patishi Y, Lubrich B, Berger M, Kofman O, van Calker D, Belmaker RH. Differential uptake of myo-inositol in vivo into rat brain areas. Eur Neuropsychopharmacol. 1996; 6:73–75.

15. Strauss GI, Knudsen GM, Kondrup J, Moller K, Larsen FS. Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure. Gastroenterology. 2001; 121:1109–1119.

16. Scaglia F, Carter S, O'Brien WE, Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab. 2004; 81(suppl 1):S79–S85.